Sleeve Gastrectomy-Induced Weight Loss Increases Insulin Clearance in Obese Mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
      Insulin Resistance* ; Hyperinsulinism*/etiology; Humans ; Mice ; Animals ; Insulin/metabolism ; Mice, Obese ; C-Peptide ; Mice, Inbred C57BL ; Weight Loss ; Obesity/etiology ; Obesity/surgery ; Insulin, Regular, Human ; Gastrectomy/methods ; Diet, High-Fat/adverse effects
    • Abstract:
      Sleeve gastrectomy (SG) successfully recovers metabolic homeostasis in obese humans and rodents while also resulting in the normalization of insulin sensitivity and insulinemia. Reduced insulin levels have been attributed to lower insulin secretion and increased insulin clearance in individuals submitted to SG. Insulin degradation mainly occurs in the liver in a process controlled, at least in part, by the insulin-degrading enzyme (IDE). However, research has yet to explore whether liver IDE expression or activity is altered after SG surgery. In this study, C57BL/6 mice were fed a chow (CTL) or high-fat diet (HFD) for 10 weeks. Afterward, the HFD mice were randomly assigned to two groups: sham-surgical (HFD-SHAM) and SG-surgical (HFD-SG). Here, we confirmed that SG improves glucose-insulin homeostasis in obese mice. Additionally, SG reduced insulinemia by reducing insulin secretion, assessed by the analysis of plasmatic C-peptide content, and increasing insulin clearance, which was evaluated through the calculation of the plasmatic C-peptide:insulin ratio. Although no changes in hepatic IDE activity were observed, IDE expression was higher in the liver of HFD-SG compared with HFD-SHAM mice. These results indicate that SG may be helpful to counteract obesity-induced hyperinsulinemia by increasing insulin clearance, likely through enhanced liver IDE expression.
    • References:
      Hepatology. 2016 Sep;64(3):760-73. (PMID: 27312543)
      Diabetologia. 2012 May;55(5):1495-504. (PMID: 22349107)
      Diabetes Care. 2013 Apr;36(4):901-7. (PMID: 23223351)
      PLoS One. 2014 Apr 16;9(4):e95399. (PMID: 24740421)
      Diagn Pathol. 2011 May 11;6:40. (PMID: 21569294)
      PLoS One. 2014 Sep 26;9(9):e108693. (PMID: 25259572)
      Surg Obes Relat Dis. 2016 May;12(4):795-802. (PMID: 26965153)
      Dan Med J. 2015 Apr;62(4):B5057. (PMID: 25872541)
      Diabetologia. 2012 Jul;55(7):1890-901. (PMID: 22538359)
      Am J Physiol. 1978 Jul;235(1):E53-62. (PMID: 677310)
      PLoS One. 2012;7(8):e42035. (PMID: 22870279)
      J Endocrinol. 2016 Jun;229(3):221-32. (PMID: 27000684)
      Physiology (Bethesda). 2019 May 1;34(3):198-215. (PMID: 30968756)
      Sci Rep. 2017 Nov 1;7(1):14876. (PMID: 29093479)
      Nat Chem Biol. 2021 Jan;17(1):20-29. (PMID: 32747812)
      Diabetes Obes Metab. 2018 Dec;20(12):2869-2875. (PMID: 30019375)
      Obes Surg. 2018 Sep;28(9):2672-2686. (PMID: 29987678)
      Diabetes Care. 2008 Feb;31 Suppl 2:S262-8. (PMID: 18227495)
      Front Physiol. 2019 May 15;10:561. (PMID: 31156453)
      Can J Physiol Pharmacol. 1983 Aug;61(8):802-7. (PMID: 6354405)
      Cell Rep. 2017 Jul 11;20(2):451-463. (PMID: 28700945)
      Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):. (PMID: 33526687)
      Biosci Rep. 2018 Jan 10;38(1):. (PMID: 29222348)
      Circ Res. 2016 May 27;118(11):1844-55. (PMID: 27230645)
      Diabetes. 2014 May;63(5):1454-6. (PMID: 24757197)
      JAMA. 2000 May 3;283(17):2253-9. (PMID: 10807384)
      N Engl J Med. 2020 Aug 20;383(8):777-778. (PMID: 32813956)
      JCI Insight. 2019 Mar 21;4(6):. (PMID: 30777938)
      Ann Surg. 2022 Nov 1;276(5):814-821. (PMID: 35880762)
      J Vis Exp. 2017 Dec 18;(130):. (PMID: 29286478)
      J Cell Physiol. 2019 Jun;234(6):9802-9809. (PMID: 30370604)
      Diabetol Metab Syndr. 2021 Feb 16;13(1):19. (PMID: 33593418)
      Am J Physiol. 1983 Aug;245(2):E155-9. (PMID: 6349380)
      Diabetes Ther. 2017 Jun;8(3):475-487. (PMID: 28484968)
      Endocr Rev. 1998 Oct;19(5):608-24. (PMID: 9793760)
      Diabetes Care. 2009 Mar;32(3):514-20. (PMID: 19246589)
      Sci Rep. 2019 Feb 12;9(1):1880. (PMID: 30755673)
      J Clin Endocrinol Metab. 2013 Nov;98(11):4391-9. (PMID: 24057293)
      PLoS One. 2011;6(6):e20818. (PMID: 21695259)
      Diabetes Care. 2016 Jun;39(6):893-901. (PMID: 27222547)
      Biochemistry. 1995 Jul 25;34(29):9341-9. (PMID: 7626603)
      Biochem Biophys Res Commun. 2020 Jun 11;526(4):1069-1076. (PMID: 32305136)
      Sci Rep. 2019 Oct 22;9(1):15154. (PMID: 31641146)
    • Grant Information:
      #2015/12611-0, #2016/17102-9, #2019/00728-0, and #2021/04664-7. São Paulo Research Foundation
    • Contributed Indexing:
      Keywords: bariatric surgery; hepatic insulin clearance; hyperinsulinemia; insulin-degrading enzyme; obesity
    • Accession Number:
      0 (Insulin)
      0 (C-Peptide)
      0 (Insulin, Regular, Human)
    • Publication Date:
      Date Created: 20230121 Date Completed: 20230124 Latest Revision: 20230201
    • Publication Date:
      20231215
    • Accession Number:
      PMC9861800
    • Accession Number:
      10.3390/ijms24021729
    • Accession Number:
      36675244